Shree Ganesh Biotech India Ltd Hits All-Time Low Amidst Continued Decline

Market Performance and Price Movement

On 13 Mar 2026, Shree Ganesh Biotech India Ltd recorded a day decline of 3.45%, underperforming the Sensex which fell by 1.20% on the same day. Over the past week, the stock has dropped 6.67%, compared to the Sensex’s 4.81% fall. The one-month performance shows a sharper decline of 12.50%, exceeding the Sensex’s 9.08% decrease. Despite a slight recovery over three months with a 9.68% loss versus the Sensex’s 11.90% decline, the stock’s longer-term performance remains deeply negative.

Year-to-date, the stock has fallen 9.68%, marginally outperforming the Sensex’s 11.85% drop. However, the one-year and three-year performances reveal a stark contrast to the benchmark, with losses of 42.27% and 51.30% respectively, while the Sensex posted gains of 1.75% and 28.99% over the same periods. The five-year performance is particularly severe, with the stock plunging 90.43% against the Sensex’s 47.90% rise. Over a decade, Shree Ganesh Biotech India Ltd’s stock price has remained flat, in contrast to the Sensex’s 203.92% appreciation.

Technical Indicators and Sector Context

The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum. Despite this, it marginally outperformed its sector on the day by 2.59%, although the Pharmaceuticals & Biotechnology sector itself has been under pressure. The Agriculture sector, related in some operational aspects, has declined by 4.31%, indicating broader sectoral headwinds.

Financial Health and Profitability Metrics

Shree Ganesh Biotech India Ltd is classified as a micro-cap company with a Mojo Score of 12.0 and a Mojo Grade of Strong Sell, upgraded from Sell on 8 Aug 2024. The company’s financial fundamentals remain weak, with operating losses contributing to a fragile long-term outlook. Its ability to service debt is constrained, as reflected by a poor EBIT to Interest ratio averaging 0.82, indicating insufficient earnings before interest and taxes to cover interest expenses.

Profitability metrics further highlight challenges, with an average Return on Equity (ROE) of only 2.62%, signalling limited returns generated on shareholders’ funds. The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, underscoring the risk profile of the stock relative to its historical valuations. Over the past year, profits have declined by 115.5%, exacerbating the stock’s 42.27% loss in market value during the same period.

Operational Ratios and Recent Results

Recent financial disclosures show flat results for the December 2025 period, with no significant improvement in key performance indicators. The Debtors Turnover Ratio for the half-year stands at 0.00 times, the lowest recorded, indicating potential issues in receivables management or revenue realisation. This ratio typically measures how efficiently a company collects its outstanding credit, and a zero turnover suggests stagnation in this area.

Shareholding Pattern and Market Position

The majority shareholding is held by non-institutional investors, which may influence liquidity and trading dynamics. The stock’s micro-cap status and limited institutional backing contribute to its volatility and susceptibility to market fluctuations. Despite the challenging environment, the stock’s recent performance has marginally outpaced the sector on certain days, though the overall trend remains negative.

Summary of Key Challenges

The stock’s decline to an all-time low is underpinned by a combination of weak financial metrics, negative earnings trends, and limited debt servicing capacity. The persistent losses and low profitability ratios have weighed heavily on investor sentiment and market valuation. Trading below all major moving averages further confirms the prevailing downward momentum.

While the broader market and sector have experienced volatility, Shree Ganesh Biotech India Ltd’s performance has been notably weaker, with significant underperformance against the Sensex benchmark across multiple time frames. The company’s micro-cap status and non-institutional majority shareholding add layers of complexity to its market behaviour.

Conclusion

Shree Ganesh Biotech India Ltd’s stock reaching an all-time low marks a critical point in its market journey, reflecting ongoing financial and valuation challenges. The data indicates a sustained period of subdued performance relative to benchmarks and peers, with key financial ratios signalling constrained profitability and debt coverage. This comprehensive analysis underscores the severity of the current situation without projecting future developments.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today